TDMS Study 61427-07 Pathology Tables
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
FINAL#2/RATS
Facility: Battelle Northwest
Chemical CAS #: 1314-62-1
Lock Date: 08/18/99
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 14 20 17 15
Natural Death 3 6 4 5
Survivors
Terminal Sacrifice 33 24 29 30
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (48) (47) (48) (49)
Intestine Small, Duodenum (48) (47) (48) (49)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50)
Hepatocellular Adenoma 1 (2%)
Mesentery (9) (20) (22) (15)
Histiocytic Sarcoma 1 (5%)
Oral Mucosa (1) (1)
Pharyngeal, Squamous Cell Carcinoma 1 (100%)
Pharyngeal, Squamous Cell Papilloma 1 (100%)
Pancreas (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Stomach, Glandular (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Tongue (2) (4) (2)
Squamous Cell Carcinoma 1 (50%)
Squamous Cell Papilloma 1 (50%) 1 (25%)
Tooth (3) (2) (2) (1)
Odontoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (50)
Adrenal Medulla (49) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Islets, Pancreatic (49) (50) (49) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (49) (50) (49) (50)
Pars Distalis, Adenoma 31 (63%) 29 (58%) 24 (49%) 30 (60%)
Thyroid Gland (50) (50) (50) (50)
Bilateral, C-Cell, Adenoma 1 (2%)
C-Cell, Adenoma 2 (4%) 4 (8%) 3 (6%) 3 (6%)
C-Cell, Carcinoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (50) (49) (50)
Adenoma 2 (4%) 3 (6%)
Carcinoma 1 (2%) 2 (4%) 3 (6%)
Histiocytic Sarcoma 1 (2%)
Ovary (50) (50) (50) (50)
Carcinoma 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Uterus (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Polyp Stromal 6 (12%) 3 (6%) 7 (14%) 13 (26%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Lymph Node (3) (3) (3) (2)
Carcinoma, Metastatic, Mammary Gland 1 (33%)
Pancreatic, Histiocytic Sarcoma 1 (33%)
Lymph Node, Bronchial (42) (45) (44) (44)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (42) (41) (45) (46)
Lymph Node, Mesenteric (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (48) (50) (50) (48)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (50) (50) (50) (50)
Thymus (49) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Adenoma 1 (2%)
Carcinoma 1 (2%) 2 (4%) 2 (4%) 3 (6%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 12 (24%) 9 (18%) 18 (36%) 18 (36%)
Fibroadenoma, Multiple 4 (8%) 4 (8%) 2 (4%) 3 (6%)
Skin (50) (50) (50) (50)
Fibrosarcoma 1 (2%)
Keratoacanthoma, Multiple 1 (2%)
Schwannoma Malignant 1 (2%)
Pinna, Neural Crest Tumor, Benign 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (2) (2)
Rhabdomyosarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Astrocytoma Malignant 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (49) (49) (50)
Histiocytic Sarcoma 1 (2%)
Lung (49) (49) (50) (50)
Alveolar/Bronchiolar Adenoma 3 (6%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Clitoral Gland 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Histiocytic Sarcoma 1 (2%)
Nose (50) (50) (50) (50)
Chondroma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Papilloma 1 (2%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Transitional Epithelium, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leukemia Mononuclear 21 (42%) 23 (46%) 22 (44%) 15 (30%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 47 46 45
Total Primary Neoplasms 93 93 96 96
Total Animals with Benign Neoplasms 41 39 41 39
Total Benign Neoplasms 64 59 64 71
Total Animals with Malignant Neoplasms 28 29 27 22
Total Malignant Neoplasms 29 34 32 25
Total Animals with Metastatic Neoplasms 2 1 2
Total Metastatic Neoplasm 3 1 2
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 25 17 18 13
Natural Death 5 4 6 10
Survivors
Terminal Sacrifice 20 29 26 27
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (49) (50)
Intestine Large, Cecum (46) (48) (45) (46)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (45) (47) (45) (43)
Carcinoma 1 (2%)
Liver (50) (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mesentery (8) (18) (12) (9)
Fibrous Histiocytoma, Metastatic, Skin 1 (13%)
Oral Mucosa (3) (4)
Squamous Cell Carcinoma 1 (25%)
Squamous Cell Papilloma 1 (33%)
Pharyngeal, Squamous Cell Papilloma 1 (33%)
Pancreas (50) (50) (49) (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Salivary Glands (49) (50) (49) (50)
Tongue (1) (2)
Squamous Cell Papilloma 1 (50%)
Tooth (7) (1) (2) (5)
Odontoma 1 (20%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Sarcoma, Metastatic, Skin 1 (2%)
Adrenal Medulla (50) (50) (49) (50)
Ganglioneuroma 1 (2%)
Pheochromocytoma Malignant 1 (2%) 2 (4%)
Pheochromocytoma Complex 2 (4%)
Pheochromocytoma Benign 4 (8%) 10 (20%) 6 (12%) 6 (12%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Adenoma 1 (2%) 3 (6%) 1 (2%) 2 (4%)
Carcinoma 1 (2%) 4 (8%) 3 (6%)
Parathyroid Gland (49) (49) (48) (48)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Pituitary Gland (50) (50) (50) (50)
Pars Distalis, Adenoma 35 (70%) 35 (70%) 39 (78%) 32 (64%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (49) (50)
Sarcoma, Metastatic, Skin 1 (2%)
C-Cell, Adenoma 1 (2%) 4 (8%) 4 (8%) 2 (4%)
C-Cell, Carcinoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (2)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (49) (50)
Preputial Gland (50) (50) (49) (50)
Carcinoma 2 (4%) 2 (4%) 2 (4%)
Testes (50) (50) (50) (50)
Bilateral, Interstitial Cell, Adenoma 21 (42%) 21 (42%) 18 (36%) 23 (46%)
Interstitial Cell, Adenoma 15 (30%) 11 (22%) 16 (32%) 11 (22%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node (2) (3) (2) (5)
Lymph Node, Bronchial (39) (44) (47) (44)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (3%)
Sarcoma, Metastatic, Skin 1 (3%)
Lymph Node, Mandibular (44) (48) (46) (45)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (50) (50) (49) (50)
Lymph Node, Mediastinal (45) (47) (46) (44)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Spleen (50) (50) (48) (50)
Thymus (49) (49) (49) (50)
Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (50) (49) (50)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 2 (4%) 2 (4%) 1 (2%)
Skin (50) (50) (50) (50)
Basal Cell Adenoma 1 (2%) 1 (2%)
Basal Cell Adenoma, Multiple 1 (2%)
Basal Cell Carcinoma 1 (2%) 1 (2%)
Fibrosarcoma 1 (2%)
Fibrous Histiocytoma 1 (2%)
Page 9
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Keratoacanthoma 3 (6%) 6 (12%) 2 (4%) 2 (4%)
Keratoacanthoma, Multiple 1 (2%)
Neural Crest Tumor, Benign 1 (2%)
Schwannoma Benign 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Trichoepithelioma 1 (2%)
Subcutaneous Tissue, Fibroma 2 (4%) 4 (8%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Lipoma 2 (4%) 3 (6%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Cranium, Sarcoma, Metastatic, Skin 1 (2%)
Femur, Osteosarcoma 1 (2%)
Mandible, Osteosarcoma 1 (2%)
Skeletal Muscle (2) (2)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Carcinoma, Metastatic, Mammary Gland 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Glioma Malignant 1 (2%)
Meningioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (50) (50) (49)
Lung (50) (49) (48) (50)
Alveolar/Bronchiolar Adenoma 4 (8%) 6 (12%) 5 (10%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Page 10
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma, Metastatic, Oral
Mucosa 1 (2%)
Pleura (2) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
Trachea (50) (50) (49) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Lacrimal Gland (1)
Fibrosarcoma, Metastatic, Skin 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (49) (50) (48) (50)
Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Leukemia Mononuclear 22 (44%) 21 (42%) 19 (38%) 17 (34%)
Lymphoma Malignant 1 (2%)
Mesothelioma Malignant 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 61427-07 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC VANADIUM PENTOXIDE Date: 11/19/01
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 10:03:59
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE CONTROL 0.5 1.0 2.0
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 50 49 49
Total Primary Neoplasms 124 147 138 120
Total Animals with Benign Neoplasms 48 47 49 46
Total Benign Neoplasms 93 108 103 93
Total Animals with Malignant Neoplasms 28 31 30 24
Total Malignant Neoplasms 31 39 35 27
Total Animals with Metastatic Neoplasms 5 4 2 1
Total Metastatic Neoplasm 19 6 7 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------